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FOREWORD 
Cardiovascular disease is defined as a disease that occurs in the heart, vascular of the brain, or 
blood vessels. However, for me, cardiovascular disease changed my life. I was 9 years old 
when my family moved to Sweden, with my father unable to join us initially. When we were 
reconnected in Sweden almost 6 months later, he had a myocardial infarction at the age of 46. 
I grew up in fear of this disease and with knowledge of associated medications and surgery. 
My degree project in high school was about myocardial infarction and bypass surgery, which 
my father had in 1994. In 2000 I lost my dear brother, aged 27 years. He was given the 
unspecified diagnosis cardiac arrest without further reason. Two years later, I also lost my 
father, whose heart could no longer manage.  
Ten years later, I was given the opportunity to fulfil mine - and my father’s - dream when I was 
offered to do research. I knew at that time that research in the area of cervical cancer would 
have been a more straight forward path, but it didn’t feel right. If I was going to do research, 
then I wanted it to be on a disease that has been a big part of my life since I was a child - 
cardiovascular disease. 
Initially, I had hoped to do research on cardiovascular disease for both younger people and 
immigrants. In particular, second-generation immigrants. Unfortunately, the data available was 
not sufficient to investigate this. This is a pity, since I know first-hand how incomprehensible 
the consequences can be for young people and families affected by this disease. 
I am not a medical doctor. I have a Masters degree in computer science and mathematics, so I 
will never be able to directly help patients with cardiovascular disease or their concerned 
families. However, I hope my research can bring a tiny little piece to the puzzle of bridging the 
gap between the most and least advantaged groups in cardiovascular disease. 
 
  
  
ABSTRACT 
Cardiovascular disease (CVD) accounts for 30% of global mortality and is the most common 
cause of death in the world. Population-wide prevention strategies as well as healthcare 
interventions have led to a decrease in CVD incidence and mortality. Socioeconomic position 
(SEP) is associated with almost the entire developmental course of CVD, from modifiable risk 
factors and atherosclerosis to incidence, survival, and mortality. 
The purpose of this thesis was to investigate how absolute and relative SEP inequalities in 
myocardial infarction (MI) and ischemic stroke (IS) have developed over time in Sweden, and 
additionally, to investigate the association between SEP and subclinical biomarkers for 
atherosclerosis, as well as with prescription of CVD preventive drugs. 
In Study I and II, record linkage of Swedish population register data and time-to-event analysis 
was used to estimate absolute and relative SEP inequalities in both MI/IS incidence as well as 
short-term and long-term case-fatality. Swedish Censuses were used to classify SEP into five 
different groups. Incidence and case-fatality of MI and IS have decreased over time in Sweden 
across all SEP groups. However, in women the reduction in incidence of MI and IS have been 
lower than for men. Over time, SEP inequalities persist between the lowest and highest SEP 
groups in MI and IS incidence and in short-term as well as long-term case-fatality in MI. 
Regarding IS, SEP inequalities in short-term case-fatality have decreased over time, but seem 
to be stable in long-term case-fatality. 
In Study III, we investigated educational differences in several subclinical biomarkers for 
atherosclerosis in the cohort "Prospective Investigation of Vasculature in Uppsala Seniors" 
(PIVUS), which includes a range of vascular- and cardiac biomarkers. By using regression 
analysis, we found associations between longer education and two vascular biomarkers as well 
as five cardiac biomarkers. Additionally we were able to demonstrate that body mass index 
mediated the associations between educational level and subclinical biomarkers for 
atherosclerosis. 
Given the overall SEP differences in CVD, it is plausible that those in disadvantaged SEP 
groups are in greater need of preventive drugs for CVD. In Study IV, we investigated whether 
there are SEP differences in the prescription of CVD preventive drugs according to need. In 
particular, we wanted to investigate SEP differences in lipid lowering drugs statins and two 
antihypertensive drugs, ACE-inhibitors and angiotensin receptor blockers (ARBs). According 
to Swedish guidelines, ACE-inhibitors are the recommended antihypertensive drugs, while 
ARBs are given as second-line treatment and have fewer side effects. We used a record linkage 
of Swedish population register data with the Swedish Drug Prescription Register. Statins, ACE-
inhibitors and ARBs were prescribed largely to socioeconomically disadvantaged groups, this 
did still not meet their needs. When accounting for need, we were able to report that 
socioeconomically advantaged groups were prescribed statins and ARBs to larger extend than 
disadvantaged groups, while almost equally prescription distributions were noted among SEP 
groups for ACE-inhibitors. 
In this thesis, we conclude that SEP differences in CVD incidence and case-fatality persist over 
time in Sweden. SEP is associated with subclinical biomarkers of atherosclerosis as well as 
CVD preventive drugs. The small inequalities in ACE-inhibitors drugs prescription across SEP 
may have contributed to the decreased SEP difference in IS short-term case-fatality, which 
suggest that SEP inequalities may be reduced by targeted guidelines. 
  
  
SAMMANFATTNING PÅ SVENSKA 
Hjärt- och kärlsjukdomar står för 30% av den globala dödligheten och är därmed den vanligaste 
dödsorsaken i världen. Både befolkningsomfattande preventionsåtgärder och 
interventionsstrategier inom hälso- och sjukvården har bidragit till minskad förekomst och 
dödlighet i hjärt- och kärlsjukdomar. Socioekonomiska position (SEP) är sammankopplad med 
nästan hela utvecklingsförloppet av hjärt- och kärlsjukdomar, alltifrån riskfaktorer, 
åderförkalkning, till insjuknande, överlevnad och dödlighet. 
Syftet med denna avhandling var att undersöka hur de absoluta och relativa socioekonomiska 
skillnaderna i hjärtinfarkt och ischemisk stroke har utvecklats över tid i Sverige. Dessutom 
undersöktes socioekonomiska skillnader i subkliniska biomarkörer för åderförkalkning samt i 
läkemedelsförskrivning för förebyggande av hjärt-och kärlsjukdomar. 
I studie I och II har vi använt oss av registerutdrag baserad på hela svenska befolkningen och 
överlevnadsanalys för att presentera de absoluta och relativa socioekonomiska skillnaderna 
dels i förekomst av hjärtinfarkt och ischemisk stroke såväl som korttids- och långtidsdödlighet. 
Folk- och bostadsräkningar har använts för att klassificera fem socioekonomiska grupper. 
Resultatet visar bland annat att förekomsten och dödligheten i hjärt- och kärlsjukdomar har 
minskat över tid i Sverige inom alla socioekonomiska grupper. Emellertid har minskningen i 
förekomsten av hjärtinfarkt och ischemisk stroke bland kvinnor varit lägre än bland män. Det 
framgår även i resultaten att de socioekonomiska skillnaderna mellan den lägsta och högsta 
gruppen kvarstår över tid för insjuknanden i hjärtinfarkt och ischemisk stroke samt i både den 
kortsiktiga och den långsiktiga dödligheten i hjärtinfarkt. Angående ischemisk stroke så har de 
socioekonomiska skillnaderna minskat över tid för den kortsiktiga dödligheten men har varit 
stabil för den långsiktiga. 
I studie III undersöktes utbildningsskillnader i olika subkliniska mått för åderförkalkning i en 
kohort ”Prospective Investigation of Vasculature in Uppsala Seniors” (PIVUS) innehåller flera 
kärl- och hjärtmarkörer. Med hjälp av regressionsanalys påvisas i resultaten att det finns 
utbildningsskillnader i kärlmarkörer och i flera hjärtmarkörer, med en effektstorlek som 
varierar mellan -0.2 till 0.1 per ökad utbildningsnivå. I analyserna konstaterades även att BMI 
(kroppsmasseindex) medierar 15-66% av förhållandet mellan utbildningsnivå och de 
subkliniska biomarkörer för åderförkalkning. 
 
Eftersom det finns socioekonomiska skillnader i insjuknande av hjärt- och kärlsjukdomar så är 
det mer troligt att de missgynnade socioekonomiska grupperna är i större behov av 
förebyggande läkemedelsinsatser för hjärt- och kärlsjukdomar. I studie IV undersöktes om det 
finns socioekonomiska skillnader i läkemedelsförskrivning för förebyggande av hjärt- och 
kärlsjukdomar i förhållande till behovet. I synnerhet undersöktes socioekonomiska skillnader i 
blodfettssänkande mediciner statiner och två olika högt blodtrycksmediciner ACE-hämmare 
och angiotensin receptor blockerare (ARB). ACE-hämmare är den rekommenderade högt 
blodtrycksmedicinen enligt sjukvårdsriktlinjer medan ARB medicinen ges som ett andra 
handsval och är dyrare medicin med färre biverkningar. Registerdata med totala svenska 
befolkningen användes och läkemedelsförskrivningen identifierades från läkemedelsregistret. 
Statiner, ACE-hämmare och ARB förskrevs i större utsträckning för socioekonomiska 
missgynnade grupper, men detta mötte inte behovet. När medicinbehovet tas med i 
beräkningen visas det att det finns socioekonomiska skillnader i läkemedelsförskrivning, 
speciellt för statiner och ARB men däremot så var socioekonomiska skillnaderna för ACE-
hämmare små. 
Avhandlingen visar på att socioekonomiska skillnader i insjuknande och dödlighet i hjärt- och 
kärlsjukdomar kvarstår över tid i Sverige och att skillnaderna kan observeras i de subkliniska 
markörerna för åderförkalkning men även i läkemedelsförskrivning i syfte att förebygga hjärt- 
och kärlsjukdomar. Den jämlika högt blodtryck läkemedelsanvändning kan ha varit en 
bidragande orsak för den minskade socioekonomiska skillnaden i kortsiktig dödlighet, vilket 
ger en indikation på att socioekonomiska skillnader kan minska med målriktade riktlinjer. 
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1 INTRODUCTION 
Every human has the right to a normal standard of living that is adequate for health and well-
being, in accordance with both human rights and dignity. Nevertheless, there are differences in 
life chances within and between countries. New-born children have over 20 years difference in 
life expectancy when comparing Sweden to many African countries.1,2 Over many decades, the 
World Health Organization (WHO) has struggled to close the gap in health inequalities both 
within and between countries.1 Many countries have established commissions and ministries 
with an equivalent aim. Reports from different parts of the world have structured and analysed 
the inequalities in health.3,4 In 2015, the Swedish Government established a commission for 
equity in health, with the aim “Avoidable health gaps must be closed within a generation”.5 
Despite this, the health gap still exists; in Sweden, the life expectancy at 30 years of age is 9 to 
10 years greater for highly educated individuals, compared to those without any formal 
education.6 
Cardiovascular disease (CVD) accounts for 30% of global mortality and is the most common 
cause of death in the world.7 There has been a dramatic improvement in the prevention and 
treatment of CVD over the years, resulting in a substantial decrease in CVD incidence, survival 
and mortality.8-10 Therefore, it is also important to ask whether we have managed to succeed in 
closing the gap in CVD inequalities, in a country like Sweden with universal healthcare. 
This thesis investigates whether the gap in CVD inequalities has been reduced over time in 
Sweden, and highlights inequalities in subclinical biomarkers of CVD and in preventing CVD 
through the use of medications.  
 2 
2 BACKGROUND 
2.1 CARDIOVASCULAR DISEASE 
The heart pumps blood that supply the body with oxygen and nutrients. The heart muscle 
receives its own blood supply from the coronary arteries. While the brain controls intellectual 
function and other organ systems. Two large vessels supply blood from the heart to the brain. 
Cardiovascular disease (CVD) is defined as heart diseases and vascular diseases both in the 
brain, and other blood vessels.7 CVD include coronary heart disease (CHD) such as MI, 
stroke and heart failure. Figure 1 shows the proportion of different forms of CVD in Sweden. 
CVD is the leading cause of death in Sweden and worldwide.7 Around 2 million deaths in 
Europe are due to CVD, accounting for 33 percent of all mortality. CVD mortality rates 
increase with age and men has higher rates than women. Several other factors may influence 
CVD mortality, such as social class or birth county.11 CVD mortality has declined sharply in 
high-income countries,12-14 and by nearly 70 percent in Sweden since 1987.15 Healthcare 
intervention strategies and primary preventions have contributed to the improvements in 
CVD mortality as well as CVD incidence rates and survival.8 The main underlying 
pathological process that leads to CVD is atherosclerosis.  
 
Figure 1. Proportion of deaths from cardiovascular diseases in Sweden [Source: Eurostat database]16 
2.1.1 Atherosclerosis 
Atherosclerosis, which develops over many years is an inflammatory process in the walls of 
blood vessels.17 Atherosclerosis is the primary cause of CVD and involves the pathological 
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deposition of lipoproteins.18 The inside of an artery narrows due to plaque forming on the wall 
of arterial blood vessels. This narrowing limits the flow of oxygen-rich blood to all parts of 
the body, which can lead to calcification, inflammation, and eventual thrombosis (Figure 
2).19,20 Atherosclerosis generally starts when a person is young, though usually without 
symptoms.21 It tends to worsen with age, and almost all people have some atherosclerosis by 
the age of 65.22 Ageing also affects arterial stiffness, which in turn accelerates the 
arteriosclerosis process.23 
 
Figure 2. Progression of atherosclerosis [Reproduced with permission from Abrams24, Copyright 
Massachusetts Medical Society] 
Atherosclerosis can affect various arteries in the body, and so different diseases may develop 
depending on the arteries affected, for example arteries in the heart, common carotid arteries 
(CCA), brain, arms or legs.  
A diagnosis of atherosclerosis or CVD is based on a blood test, physical examination, 
electrocardiogram (ECG), Doppler ultrasound, or stress test exercise, among others. Great 
efforts have been made to identify useful atherosclerosis biomarkers,17,25-27 including 
endothelial dysfunction (reduce blood flow in the arteries),28 plaque rupture in the carotids, 
and left ventricular (LV) geometry. 
 4 
2.1.2 Myocardial infarction 
Myocardial infarction (MI), occurs when part of the heart is damaged due to blood supply 
decreases or even stops.7 MI usually is caused by a rupture of plaque in the atherosclerosis 
process, which lead to closure of an artery, due to clots. Angina or chest pain is the most 
common symptom, but also pain in the back, or shoulder are also common.29 However those 
symptoms are more usually common among men, where women may have other symptoms 
such as fatigue or pain in the neck or arm.30-34 
The mean age for MI in Sweden is 70 years for men and 76 years for women. The incidence 
of MI has decreased substantially in Sweden over the last two decades. In 2017, over 26,000 
MI events occurred in Sweden, corresponding to about 340 events per 100,000 inhabitants. The 
incidence increases with age, with a greater incidence among men than women. 
Overall, MI mortality has decreased by over 70% from 1987 to 2017 in Sweden. Among people 
aged 70-79, MI mortality has decreased by over 80% from 1987 to 2017 among both men and 
women.35 The largest mortality decrease was due to both improvements in the prevention of 
MI incidence and better survival after MI.8 Figure 3 illustrate trends in incidence and mortality 
rates of MI in Sweden. 
 
Figure 3. MI incidence and mortality rates per 100,000 inhabitants, 20 years and older by sex from 1987 to 
2018 [Data source: Swedish National Patient register (NPR) and Swedish Cause of death register (CDR) from 
National Board of Health and Welfare].36 
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Case-fatality rate (CFR), defined as the proportion of individuals that died after a MI event, has 
been used as a proxy measure of hospital performance and quality of care for comparison 
within and between countries.37,38 On average, a quarter of all MI events are fatal,36 although 
the definition of fatal and non-fatal varies between studies. A fatal MI is often seen as death 
within one day, although some studies define fatal as death within 28 days. Fatal and non-fatal 
MIs refer to different proxies of care. A fatal MI event indicates limited possibilities of 
healthcare and therefore can be used as a proxy for severity of care, access to ambulatory care 
and time delay to hospital care.39 On the other hand, non-fatal MI events have the opportunity 
to undergo treatment and access hospital care.39 There has been a sharp decrease in MI case-
fatality, both short-term and long-term, over time in Sweden (Figure 4).15,40 
 
Figure 4. One-day and one-year case-fatality rates (CFRs) in MI, for individuals ages 20 years and older by sex 
from 1987 to 2018 [Data source: NPR and CDR from National Board of Health and Welfare].36 
2.1.3 Stroke  
Stroke is the third most common cause of death in western populations, after CHD and cancer. 
Stroke occurs when blood flow to the brain is decreasing. The two main types of stroke are: 
ischemic stroke (IS) and hemorrhagic stroke, the latter occurs due to bleeding. IS accounts for 
around 87% of all strokes, and occurs when the cerebral artery supplying blood to the brain is 
blocked. Usually the plaque in CCA ruptured and clots blocks the CCA of the neck or blocks 
the blood vessel that feeds the brain. An interruption of blood flow for more than some minutes 
may results in brain damage.  
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The symptoms of IS vary greatly and depend on the brain region affected. Common symptoms 
include blindness, weakness in some parts of the body, dizziness, double vision or difficulty in 
speaking.41 The severity of IS range from mild to severe and may be permanent.  
The risk of IS increases with age, and is higher for individuals with a personal or family history 
of stroke. The mean age for IS is 73 years in men and 77 years in women. Men are also more 
likely to develop and die of IS than women.42,43 
Stroke mortality rates have been declining in Sweden and worldwide.44 About two thirds of 
the decrease in stroke mortality is due to improvements in case-fatality, with the remainder 
being due to reduced incidence.45 
Rapid decrease in IS incidence, by up to 30%, has been reported in Europe and Sweden. 46-51 
However, decrease in IS incidence has mainly been among the elderly, and remains unchanged 
or possibly increasing among younger people. 48-50 Figure 5 illustrate trends in incidence and 
mortality rates of IS in Sweden. 
 
Figure 5. IS incidence and mortality rates per 100,000 inhabitants, 20 years and older by sex from 1987 to 2018 
[Data source: NPR and CDR from National Board of Health and Welfare].36 
Decline in case-fatality of IS has also been reported in recent decades.46,52 Both short-term case-
fatality and long-term case-fatality have improved in Sweden (Figure 6). On average, one-year 
case-fatality rates have decreased by 25% in Sweden in the last two decades.51  
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Figure 6. One-day and one-year case-fatality rates (CFRs) in IS, 20-85+ years by sex from 1987 to 2018 [Data 
source: NPR and CDR from National Board of Health and Welfare].36 
2.1.4 Risk factors 
Risk factors for atherosclerosis can be classified into unmodifiable and modifiable risk 
factors.11 Age, sex and family history are seen as unmodifiable risk factors. About 90% of 
CVD burden is attributable to modifiable risk factors.47 Smoking, heavy alcohol consumption, 
obesity and physical inactivity are some of the common modifiable risk factors for 
atherosclerosis.11,18,53-61 Smokers have twice the risk of developing atherosclerosis compared 
to non-smokers.62,63 Heavy alcohol consumption has also been associated with IS, although 
moderate alcohol consumption is often suggested to be protective.64  
Over time, poor modifiable risk factors may results in high blood pressure (hypertension), 
obesity, diabetes or higher blood lipids (dyslipidemia), which all lead to atherosclerosis and 
CVD.59,61,65-68 Other risk factors that have been associated with atherosclerosis and CVD are 
socioeconomic position, oral contraceptives, inflammation and infections.17,69,70 
Risk factors for MI and IS are generally similar to those for atherosclerosis.71 However, 
hypertension causes about 50% of all IS, making it the single most important risk factor for 
IS.61,72,73 In fact, high blood pressure is more important for IS than for other CVD, independent 
of other risk factors.74-76 Although lipoproteins are also associated with IS,61,65 those 
associations are more modest for IS than for other CVD.77  
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Reductions in modifiable risk factors, such as cigarette smoking 78 account for almost half of 
the decreased mortality, while the other half of the mortality decrease is attributed to 
improvements in medical treatment and surgery, for example, treatments to better control 
hypertension and cholesterol, improved healthcare development and timely use of 
thrombolysis in the acute phase.8,78,79 
Decreasing trends in several of modifiable risk factors for atherosclerosis such as 
hypertension, lipoproteins and smoking, have been noted both in Sweden and in many 
European countries. However, other modifiable risk factors for atherosclerosis have increased 
such as obesity and diabetes.80 
2.1.5 Drug use and pharmacoepidemiology 
Reducing high blood pressure and high blood cholesterol, both risk factors for CVD events, 
are important goals in medical treatment.  
Statins are the first-line drug treatment for high blood cholesterol. Statins have been widely 
used in treatment after CVD event (secondary prevention). However later, statins have been 
found to benefit individuals without any CVD event, and therefore even prescribed as primary 
prevention.81-84 Statins have been found to reduce the risk of all-cause mortality by 13% and 
CVD by 25% in individuals without prevalent CVD.85 
Hypertension is the most important risk factor for CVD and death worldwide. Overall, 
antihypertensive therapy is associated with a 25% reduction in the incidence of CVD and a 
38% reduction in the incidence of stroke.86-89 These reductions are substantial and generally 
remain constant across all groups of patients, regardless of age, sex and smoking habits.90 A 
recent systematic review showed that antihypertensive drugs reduced the risk of all-cause 
mortality by 14%, CHD by 16% and stroke by 36% among individuals without prevalent 
CVD.85 Additionally, small reduction in systolic blood pressure may reduce the risk of CVD 
by a quarter.91 
2.2 SOCIAL EPIDEMIOLOGY 
The term socioeconomic position (SEP) refers to individual’s position in the social structure of 
society, where some individuals have more resources and better life chances than others. Social 
epidemiology examines the relationship between social factors and different diseases.92 SEP 
can be measured on a group level - for example neighborhood deprivation, - or on an individual 
level – such as achieved education, income, occupation, or a combination of several of these 
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measures.93 While the various indicators of SEP are often used interchangeably, they each have 
a different theoretical explanation and underlying mechanism.93-95 Despite the differences, all 
these measures of SEP see lower levels being linked to poorer material and immaterial 
resources, poorer lifestyle behaviors, worse health and higher mortality.  
2.2.1 Educational level 
One of the oldest and most used proxies for social class is highest achieved level of education, 
which has the advantage of a naturally ordered scaling. Educational level is usually fixed in 
early adult life, and thus reduces some of the risk of selection bias.93 Education remains 
constant, even when poor health in mid-life may result in loss of job or income. In Sweden, 
education is compulsory from age 6 to 15, and is tax-financed for all permanent residents. 
Attained level of education is relevant as a mechanism in occupational advancement and is 
highly predictive of income and wealth.92 Education has been strongly associated to health and 
to health determinants, such as health behaviors and preventative service use. Despite this, 
trends in educational attainment have changed over time, due to changes in educational system 
in Sweden. Large educational reformers were implemented in Sweden in the 50’s and 60’s, 
which resulted in larger part of the population had access to higher education.96 Among older 
cohorts, fewer people, in particular women, had the opportunity to achieve a higher level of 
education. Therefore, comparisons between age cohorts, between sexes and across 
geographical regions can be difficult.97 
2.2.2 Occupational class 
An important indicator of social class is employment status or occupation.98 These measures 
indicate social prestige and connections, as well as reflecting economic situation, such as 
income.93,99 In addition, occupation can also reflect different aspects of the labor market, such 
as activities and circumstances of a job, hierarchical position, technical and social skills.100 
Furthermore, occupation has a direct impact on circumstances relevant for health, through the 
physical and psychological environment of the workplace itself.93 There have been substantial 
changes in class differences over time, where women, for example, have nowadays more access 
to the labor market. The household’s highest level of occupation has occasionally been used 
instead of individual measures as an indication of a family’s SEP.101 Unlike education which 
is usually fixed in early adult life, occupational class may vary over time, which may be a 
reason why occupational class is considered a better predictor than education, when measuring 
the inequalities over time.97,102 Different classification systems can be used for SEP; it can be 
measured as individuals own occupation or household’s highest level of occupation, but also 
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as a composite measure, e.g. occupation and education.101 Among others, the Erikson and 
Goldthorpe’s class schema103 combines occupational class with educational requirements to 
generate a summary of socioeconomic index (SEI), which we will use in Study I, II and IV and 
will be explained in more detail in section 4.1. 
2.3 SOCIAL DETERMINANTS 
The conditions and circumstances such as childhood circumstances, school, work conditions, 
the healthcare system and the distribution of money in society (welfare) are known as social 
determinants (Figure 7).1 All these conditions shape our opportunities for obtaining and 
maintaining good health. There are three main pathways between socioeconomic inequalities 
and health.104-106 Firstly, social causation defines the process whereby SEP affects health 
conditions. Secondly, health selection defines the process that health conditions can lead to 
differences in SEP. Thirdly, indirect selection, which indicates the case in which certain factors 
inﬂuence both SEP and health. This thesis focuses on the health social causation pathway. 
 
 
 
Figure 7. Social determinants of health reflecting the social structure of health [Source: Dahlgren and whitehead, 
1991].107 
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2.4 SWEDISH HEALTHCARE SYSTEM  
In Sweden, the state has the responsibility for establishing health policies, while the funding 
and provision of services is determined at the county and municipality levels. The Swedish 
healthcare system is largely tax-financed and aims to ensure everyone has equal access to 
healthcare services. Horizontal equity mean that individuals with the same level of need should 
have same level of healthcare access.108,109 Access to healthcare should be equal irrespective 
of individuals’ age, sex, country of birth, religion, SEP and other social factors. The Swedish 
healthcare act110 is based on horizontal equity and has two main goals: 1) “Healthcare shall be 
provided with respect for the equal value of all humans, and for the dignity of individual human 
beings. Those who have the greatest need of health and medical care shall be given precedence 
to care”; and 2) “health and medical care shall work to prevent ill health.”  
2.5 SOCIOECONOMIC INEQUALITIES IN CARDIOVASCULAR DISEASE 
There is vast evidence of SEP inequalities in CVD, both in Sweden and worldwide. SEP 
gradients have been found during the process of CVD development, for almost all modifiable 
risk factors, such as smoking and higher body mass index (BMI),111,112 but also for SEP and 
clinical conditions such as hypertension, high blood lipids and atherosclerosis.40,113-117. In 
addition, CVD morbidity, survival after a CVD event and CVD mortality differs by SEP.40,117-
123 Furthermore, inequalities in access to coronary procedures before and after a CVD event, 
such as revascularization and coronary angiography, have been reported124-126 and this is also 
the case for recurrence of a CVD event.127 
As mentioned previously in sections (2.1.22.1.3) there have been large reductions in CVD 
mortality and incidence over time as well as improvements in CVD case-fatality. Contradictory 
findings on how those improvements are distributed across SEP have been reported. Some 
studies have found that inequalities in CVD have increased,120,128-130 while recent data from 
Swedish National Board of Health and Welfare (Socialstyrelsen) show that educational 
inequality in MI incidence has been stable over time in Sweden see Figure 8. 
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Figure 8. Relative differences by educational level in age standardized (45─74 years) MI incidence, among men 
and women from 1991 to 2018. Primary school (Low), Secondary school (Middle) and University or College 
(High) [Data source: NPR and CDR from National Board of Health and Welfare, Educational Register from 
Statistical Sweden].131 
How to measure inequalities in health has been debated since long. Mackenbach et.al reported 
that relative inequalities in overall mortality are largest in Sweden and Norway among western 
European contries.132,133 Vågerö et.al. argue that reporting only relative measures of inequality 
is misleading, absolute levels of inequality indicators need to be considered as well.134 Changes 
in small absolute differences give higher relative differences than stable high absolute 
differences. A decrease in the gap between different SEP groups is not always a positive trend, 
because it could be due to an increase in unhealthy behaviors in all SEP groups, as has been 
found for overweight.97 Whether health inequalities are increasing or decreasing is an important 
question for public health policies. 
In this thesis we will report both absolute and relative measures of SEP inequalities in CVD 
incidence and case-fatality.  
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2.5.1 Socioeconomic inequalities in drug use 
Several studies have report an association between SEP and CVD drug use in Sweden and 
elsewhere.135,136 Most studies find either equal drug use by SEP, or that low SEP groups tend 
to use more CVD drugs than higher SEP groups. Importantly, high drug use among low SEP 
groups is most likely due to differences in health needs between SEP groups. Individuals in 
disadvantaged SEP groups have increased exposure to more unhealthy behaviors and therefore 
have a higher risk of developing conditions that require prescribed drugs, for example, 
hypertension, higher cholesterol, MI or IS.137 A Swedish study found that, for the general 
population and for most drug types, there was a social gradient in drug prescription.138
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3 AIMS 
This thesis examines whether SEP inequalities in CVD have changed over time in Sweden, and 
whether there is a social gradient in distribution of subclinical biomarkers and in prevention 
treatment of CVD. The following specific aims were addressed within the framework of this 
thesis. 
Study I: To investigate whether socioeconomic inequalities in MI and IS incidence have 
changed over two decades in Sweden.  
Study II: To investigate whether socioeconomic inequalities in case-fatality rates of MI and 
IS have changed over two decades in Sweden.  
Study III: To investigate the association between educational level and vascular- as well as 
cardiac biomarkers. 
Study IV: To investigate whether CVD preventive drugs are equally prescribed to individuals 
across different SEP groups, while accounting for treatment needs. 
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4 MATERIALS AND METHODS 
4.1 SWEDISH NATIONAL REGISTERS 
Study I, II and IV in this thesis used record linkage data from several Swedish national and 
population register. The National Board of Health and Welfare (Socialstyrelsen) holds the 
Swedish national health registers and Statistics Sweden (Statistika centralbyrån) holds the 
Swedish national population register and the national Censuses. Individuals are identified 
through a unique personal identity number (PIN), which has been assigned to all Swedish 
residents since 1947.139 Each individual is given an ID alias within the system that allows the 
authorities to link data from different registers, while ensuring the PIN and identity of all 
individuals remains protected. Study I and II, use the same linked data for individuals born up 
to 2002 (Figure 8). Study IV, used another data linkage, including individuals born up to 2013 
(Figure 8). 
 
 
Figure 8. Swedish national registers used in Study I, II and IV 
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The Total Population Register (TPR) includes demographic information such as date of birth, 
sex, country of birth, county of birth, emigration date, migration date and death date. The TPR 
is hosted by Statistics Sweden and includes all living individuals since 1968.  
Swedish Population and Housing Censuses: The Censuses were performed every 5 years 
from 1960 to 1990.140 The questionnaire were sent to all nationally registered Swedish residents 
(aged 16 years and older) and were mandatory. In cases of illness, individuals unable to 
complete the questionnaire were permitted to have a relative to complete it on their behalf. The 
response rate has been very high, 99% in 1980 and 98% in 1990.141,142 
The Censuses include detailed information on education, income, occupation, social class, 
housing information, and civil status.141,142 For occupation, individuals were asked “To which 
occupation do you want to count your job: Enter the occupation that describe your job as 
accurately as possible.” 
Occupations were then verified with the Labor market register.143 Socioeconomic index (SEI) 
was then derived for all individuals in the labor force, and based on Erikson, Goldthorpe, 
Portocarrero’s (EGP) class schema.144 Distinguishing between self-employed and employees, 
employees were then further classified into working in manual or non-manual occupations. 
Within both the manual and non-manual groups, individuals were also classified into low or 
high, based on the educational requirement for each occupation (see section 2.2.2).144  
In Study I, II and IV in this thesis, we selected SEI from the 1990 Census. For individuals with 
missing information, SEI was retrieved from the 1980 Census. In Study I, II and IV, SEP was 
the main exposure and was classified into five groups, from the most advantaged to 
disadvantaged: high non-manual (HN-M), low non-manual (LN-M), self-employed including 
the farmers (SE), high manual (HM), and low manual (LM) see Table 1. 
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Table 1. Socioeconomic Index according to EGP class schema and SEP category. 
SEP SEI group Delineations Example of occupation 
HN-M 46, 56, 57 Non-manual employees 
normally requiring 
university/collage 
education 
Physician, teacher  
LN-M 33, 36 Assistant non-manual 
employees normally 
requiring two years of 
secondary school education 
Nursing assistant 
SE 60, 79, 89 Self-employed with and 
without employees, small-
scale and large scale 
farmers 
Self-employed IT-consultant, 
craftsman 
HM 21, 22 Production employees 
normally requiring at least 
two years of secondary 
school education 
 Construction workers 
LM 11, 12 Production employees 
normally requiring less than 
two years of secondary 
school education 
Cashier 
 
The Swedish National Patient register (NPR) was established regionally in 1964 but became 
nationwide in 1987. Since it was initiated, the register has contained information of all inpatient 
care in Sweden, and by 1983 had achieved 88% coverage for inpatient care145 Later, the NPR 
has also included day surgery since 1997 and outpatient care since 2001. Data from primary 
care is not included in the register. Within the register, diagnosis upon discharge is classified 
according to the Swedish International Classification of Diseases (SE-ICD) which is adapted 
from the WHO ICD code classification, ICD 8 (years 1968-1986), ICD 9 (years 1987-1997), 
ICD-10 (years 1997- on going), for Skåne county ICD-10 started in 1998 instead of 1997.145 
For Study I and II, the main diagnosis were identified as the first occasion of incidence of MI 
and IS. In Study IV, both main and all secondary diagnoses were used to classify the CVD 
diagnosis. The ICD codes used for each study in this thesis are presented in Table 2. The 
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validity of the NPR is high, with the overall positive predictive values of inpatient-care 
diagnoses being 85-100%, and 98-100% for MI and IS, respectively.145 
Table 2. List of diagnosis used in the thesis by different ICD codes versions. 
Diagnosis ICD-8  
(years 1987 – 1996) 
ICD-9  
(years 1987 – 1996) 
ICD-10  
(years 1997 – 2010) 
Myocardial infarction 410 410 I21 – I22  
Ischemic heart disease 410 – 411 410 – 411  I200, I21 – I22 
Ischemic stroke 432 – 434 433 – 434 I63 
Stroke 432 – 437 433 – 436 I63 – I66, G45, G46  
Diabetes 250 250 E10 – E14 
 
Swedish Cause of death register (CDR) The cause of death register is hosted by the Swedish 
National Board of Health and Welfare, and updated annually. And includes all deaths in 
Sweden, excluding stillbirths.146 The CDR contains data from 1961, although there is also 
historical data for 1952–1960.147 For each death in Sweden, a cause of death certificate must 
be completed by a doctor and sent to the National Board of Health and Welfare.  
The causes of death reported follow the international classification of Diseases ICD-codes and 
include both the main cause of death and several secondary death diagnoses. 
The quality of the cause of death register is affected by a variety of factors, such as how cause 
of death is determined, the processing method, and what cause of death classification is used. 
Missing cause of death data in CDR has been at around 2% in recent years.146,148 
The Swedish Prescribed Drug Register (SPDR) was established in June 2005 and contains 
information on all prescribed drugs that has been dispensed in Sweden.149 However, SPDR do 
not include drugs that were prescribed but not collected. The SPDR is hosted by the National 
Board of Health and Welfare and includes more than 100 million records per year, which makes 
it one of the largest pharmacoepidemiological databases in the world. All drugs in SPDR are 
classified according to Anatomical Therapeutic Chemical Classification system (ATC), the 
drugs used in this thesis is presented in Table 3. The SPDR contains information on, among 
other things, ATC, drug name, dose, package size, cost, defined daily dose, prescription date, 
and dispense date. Swedish prescriptions should be for a maximum 3-month supply and be 
valid for no more than a year.  
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Table 3. ATC codes used in the thesis 
Drugs ATC 
Statins C10AA 
Angiotensin-converting enzyme (ACE) inhibitors C09A 
Angiotensin II receptor blockers (ARBs) C09C 
Diabetes A10A, A10B 
4.2 PROSPECTIVE INVESTIGATION OF VASCULATURE IN UPPSALA 
SENIORS (PIVUS) 
Study III was based on the PIVUS study, hosted by Uppsala University. A detailed description 
of PIVUS can be found elsewhere.150-153 In 2001, a random sample of 2,025 men and women 
aged 70 living in Uppsala were invited to participate, with 1,016 individuals (50.1%) agreeing 
to participate. Participants were asked to fill in a questionnaire including questions about their 
education, medical history, medication use, smoking habits and alcohol consumption. They 
also collected anthropometrical measures, and a seven day food diary. In Study III, the 
exposure of interest was highest achieved educational level, which was based on the question 
read as follows: “What is the highest educational level you have completed?” (1=Primary 
school; 2=Secondary school; and 3= University or College). 
Several physical tests were also performed to evaluate several atherosclerosis biomarkers, for 
a total of four hours. There was at least 30 minutes rest between different tests. The tests 
included endothelial function, arterial compliance, echocardiographic test, and ultrasound of 
the CCA. In addition, blood samples were taken to measure the lipids and blood glucose 
variables with standard laboratory techniques, and blood pressure was measured, and a mean 
of three measurements was used.  
We divided the evaluated atherosclerosis biomarkers from the PIVUS study in two groups; 
vascular- and cardiac biomarkers. In total we used eight vascular biomarkers and seven cardiac 
biomarkers. 
The seven cardiac biomarkers were obtained by using a two-dimensional echocardiography 
Doppler examination, and was performed approximately one week after the main examination. 
The echocardiography, one of the most widely used diagnostic test of CVD, show the heart 
structure with the blood flow. The measures include left ventricular (LV) geometry and 
function, which are used to define LV dysfunction that is associated with atherosclerosis and 
CVD.154 Additional measurements of the LV are left atrial dimension (LA), as well as LV 
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diameter at end diastole (LVEDD). Calculation of LV relative wall thickness (RWT) was 
obtained as (interventricular septal thickness + posterior wall thickness) divided by LVEDD, 
and LV mass index was obtained by indexing LV mass divided by height to the power of 2.7 
(LVMI/m2.7).155,156 Ejection fraction (EF) was calculated from LV volumes according to the 
Teichholz formula.157 Additionally, the LV isovolumic relaxation time (IVRT) was measured 
as time between aortic valve closure and the start of mitral flow. The ratio between the peak 
velocity blood flow from LV relaxation in early diastole (E wave) and the peak velocity of 
atrial filling (A wave) (E/A ratio) was calculated, which is a marker of the function of the LV. 
All of these biomarkers have been associated to atherosclerosis and CVD.158-164 
The eight vascular biomarkers were obtained by four different tests: 1) The invasive forearm 
technique, 2) The brachial artery ultrasound technique, 3) CCA ultrasound technique and 4) 
Arterial compliance by pulse wave analysis. 
Both the invasive forearm test and the brachial artery ultrasound were performed to assess the 
endothelial dysfunction. Endothelial dysfunction, which is the process of damaging the arterial 
wall, has been considered as an early marker for atherosclerosis.165 The invasive forearm test 
was performed by venous occlusion plethysmography, as an arterial cannula was placed in the 
brachial artery to measure forearm blood flow (FBF). Resting FBF was measured as well as 
FBF after infusions of two drugs (Acetylcholine and Sodium nitroprusside) to define 
endothelium-dependent vasodilation (EDV) and endothelium-independent vasodilation 
(EIDV), more details can be found elsewhere.151 The second technique, the brachial artery 
ultrasound was assessed by external B-mode ultrasound to measure the non-invasive 
endothelial dysfunction, flow-mediated vasodilation (FMD).166 FMD was defined as the 
brachial artery maximum diameter after a cuff release minus diameter at rest divided by 
diameter at rest. The third technique was also assessed by external B-mode ultrasound imaging 
of the CCA, which has been described in more detailed previously.153 As described before 
(section 2.1.3), plaque in the CCA is a marker for atherosclerosis and one key for developing 
IS.167 Both sides of the CCA were visualized to search for occurrence of plaque and number of 
plaques in CCA was noted. The CCA far wall was evaluated 1-2 cm to the bulb and intima-
media (IM) thickness (IMT) were estimated, which is widely accepted as a marker for 
atherosclerosis and a predictor of CVD.168-170 A region of interest (ROI) was manually placed 
around the IM and a program evaluated the grey scale median (IM-GSM),153 which has been 
found to be an easy measurement of the CCA wall.153 From the fourth technique, the pulse 
pressure ratio (PP) was evaluated to enable the calculation of CCA distensibility as the 
percentage change of CCA diameter from maximum to minimum divided by PP. The CCA 
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distensibility, which has been linked to several factors that lead to atherosclerosis and 
CVD,171,172 is a measure of the ability of the artery to expand and contract in the process of 
pulsation and relaxation.173 The ratio of stroke volume (measured from ECG) divided by PP 
(SV/PP) was also calculated, which is a an index of large artery elasticity,174,175 and has been 
found to be a marker for atherosclerosis and CVD.176 
While the PIVUS study includes a follow-up both at age 75 and 80, Study III in this thesis uses 
only baseline data at age 70 years. 
4.3 STATISTICAL METHODS 
4.3.1 Linear regression and multiple regression 
Linear regression is used to model the association between a dependent variable/outcome Y 
and an independent variable/exposure X. A model with two or more independent variables (X1, 
X2 etc.) is called a multiple regression model. Conventionally, regression models are based on 
several assumptions: fundamentally, the outcome variable needs to be on a continuous scale, 
and the relationship between outcome and predictors needs to be linear. Additionally, we 
usually assume that the observed data includes an error term that is on average zero, with 
constant variance and normal distribution. This is usually written as 
𝑌 = 𝛽଴ + 𝛽ଵ𝑋ଵ + 𝛽ଶ𝑋ଶ + 𝜀 
where 𝛽଴ is the excepted outcome value when all predictors are set to zero (intercept), 𝛽ଵ 
and 𝛽ଶ are slopes measuring the expected change in outcome associated with a +1 change 
in the corresponding predictor variables, and 𝜀 is a normally distributed error term with 
mean zero and fixed variance.  
Multiple linear regression was used in Study III to model the association between 
educational level and continuous atherosclerosis biomarkers. 
4.3.2 Logistic regression 
Logistic regression generalizes the linear regression model for a binary variable outcome 
variable Y, usually coded as 0 (no event) and 1 (event). The logistic regression model connects 
the transformed event probability P with the given predictor variables (X1, X2, etc.) The 
transformation that defines the logistic regression is the log-odds, or logit function, where the 
odds of an event is defined as the ratio of the event probability divided by the probability of 
that the event not occurring:  
  23 
𝑙𝑜𝑔𝑖𝑡(𝑃) = 𝑙𝑜𝑔 ൬
𝑃
1 − 𝑃
൰ 
 
The logistic regression model assumes that the underlying events follow a Bernoulli 
distribution with event probability P, and that the corresponding log-odds are a linear function 
of predictor variables:  
𝑙𝑜𝑔𝑖𝑡(𝑃) = 𝛽଴ + 𝛽ଵ𝑥ଵ + 𝛽ଶ𝑥ଶ 
In analogy to the linear regression model above, 𝛽଴ is the intercept, and 𝛽ଵ and 𝛽ଶ are slopes 
that describe level and change of the logit as function of the predictor variables. 
Exponentiating this linear equation to get a multiplicative equation for the odds 
𝑂𝑑𝑑𝑠 =
𝑃
1 − 𝑃
= 𝑒ఉబାఉభ௫భାఉమ௫మ  
can be used to show that 𝑒𝑥𝑝(𝛽ଵ) and 𝑒𝑥𝑝(𝛽ଶ) are the odds ratios associated with a +1 change 
in the corresponding predictor variables.  
This model can be generalized to situations where the discrete outcome variable Y has more 
k>2 categories: the multinomial logistic regression model uses k-1 parameters for each 
predictor variable, corresponding to one odds ratios each for k-1 outcome classes relative to 
a freely chosen reference outcome class. However, if the k outcome categories are ordered, 
this model can often be simplified again to an ordinal logistic regression model, which uses 
one parameter per predictor variable. Same as for the binary logistic regression model: the 
necessary assumption here is that of proportional odds ratios, i.e. that the odds ratio for an 
outcome class relative to the next-smaller class is the same for all classes. 
Logistic regression was used in Study II to model the odds ratio of the binary outcome short-
term case-fatality (death within one day) of MI and IS. Ordinal logistic regression was used in 
Study III for the association between educational level and the ordinal categorical outcome 
number of plaques in CCA.  
4.3.3 Survival analysis  
Survival analysis is a statistical technique for modelling the time until an event occurs. 
Individuals are followed from a certain point in time – such as birth or diagnosis – until an 
event occurs, e.g. CVD diagnosis or death. Sometimes, when individuals cannot be followed 
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until the event occurs, e.g. due to migration or end of study, we only know that the event time 
is greater than the end of follow-up, when we say that there is right censoring.  
Survival analysis is able to account for this loss of information and individual data can still be 
included in the models calculations: each individual i is followed until time ti on some 
underlying timescale (e.g. time since birth), until either the event of interest occurs or censoring 
takes place. To distinguish between event times and censoring times, all individuals have an 
event indicator di that takes the value one if the individual experienced the event or zero if the 
individual was censored.  
If the probability density function for the survival time T is f(t), the cumulative distribution 
function F(t) is then 
𝐹(𝑡) = න 𝑓(𝑡)
௧
଴
 
Models for survival data are generally based on two related functions, the survival function S(t) 
and the hazard function h(t). The survival function is simply the probability of survival beyond 
time t, or in other words, the probability that the survival time is greater than time t: 
𝑆(𝑡) = 𝑃(𝑇 > 𝑡) = 1 − 𝐹(𝑡) 
The hazard function h(t) is the instantaneous event rate at time t, conditional on surviving up 
to time t: 
ℎ(𝑡) = 𝑙𝑖𝑚
∆௧→଴
𝑃(𝑇 < 𝑡 + ∆𝑡 | 𝑇 ≥ 𝑡)
∆𝑡
 
A related measure of event risk is the cumulative hazard function, which aggregates the 
instantaneous hazard over time: 
𝐻(𝑡) = න ℎ(𝑦)𝑑𝑦
௧
଴
 
A common assumption for survival models is that of proportional hazards: this refers to a 
situation where the ratio of two hazard functions for different values of the predictor variables 
in the model is constant over time. In a simple example, the hazard ratios for exposed and 
unexposed subjects he(t) and hu(t) are both functions of time t, but under the proportional hazard 
assumption, their ratio λ= he(t)/hu(t) is constant over time. 
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This simple assumption has important implications for the survival model: practically, it allows 
us to summarize the relative risk of an event between exposed and unexposed subjects simply 
by one number λ, the hazard ratio. Theoretically, it implies that the hazard function can be split 
into the product of two components, one that only depends on the observed times, and one that 
only depends on the predictor variables in the model; this corresponds to a sum of two 
components for the log-hazard function, e.g.: 
log[ ℎ(𝑡, 𝑥ଵ, 𝑥ଶ) ] = 𝑠(𝑡) + 𝑔(𝑥ଵ, 𝑥ଶ) 
Here, the function 𝑠(𝑡) is referred to as (log-) baseline hazard. 
4.3.4 Flexible parametric model  
In its basic form, a flexible parametric survival model (FPM),177-180 is a proportional hazard 
model that fits the log cumulative hazard as a smooth function of the observed time at risk,181 
without explicit parametric assumptions about the underlying survival function S(t), and 
assuming linear effects of the predictor variables on the chosen scale:  
log[ 𝐻(𝑡, 𝑥ଵ, 𝑥ଶ) ] = 𝑠(log(𝑡)|𝑘) + 𝛽ଵ𝑥ଵ + 𝛽ଶ𝑥ଶ 
Here, 𝑠(⋅ |𝑘) is the baseline hazard of the survival model, which is fitted as a restricted cubic 
spline function. A cubic spline is a smoothing function consisting of pieces of cubic 
polynomials, joined together through a set of control points, called knots (k in the equation); to 
ensure the smoothness of the resulting function, the splines are forced to have the same first 
and second derivative at both sides of a knot; the restriction is the requirement that the 
smoothing function continuous linear outside of the range of the observed data (here: observed 
times), which stabilizes estimation at the edges. In the proportional hazard setting, the 
parameters 𝛽ଵ and 𝛽ଶ are the log-hazard ratios associated with a change of +1 in the 
corresponding predictor variables X1 and X2.  
The FPM can be seen as an extension of the parametric Weibull model that replaces the simple 
linear baseline hazard of the Weibull model with a flexible, data-driven smoothing function 
that does not correspond to any specific distribution function for the event times. The FPM can 
also be extended to non-proportional hazards, by including interactions with the (log-) 
timescale via additional spline functions.  
In practice, the FPM combines convenient estimation of smooth hazard- and survival functions 
(as for parametric survival models) with the absence of strict parametric assumptions (as for 
the Cox model). However, the FPM is only as flexible as the underlying splines, and may have 
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problems with situations where many events happen in a short interval of time, corresponding 
to a spike in the hazard function.  
We used the FPM in Study I to estimate the incidence rates (IR) and incidence rate ratios (IRR) 
of MI and IS by SEP, with calendar year as the underlying timescale. In Study II, we used the 
FPM to estimate case-fatality rates (CFR) and CFR differences (CFRD) for long-term case-
fatality after an MI/IS event, with time since disease event as the underlying timescale. 
4.3.5 Poisson model 
Like the logistic regression model, the Poisson model is a generalization of the linear regression 
model; it relates Poisson-distributed count data to a linear function of the predictor variables 
via the log-transform (instead of the logit). However, the model can also be used to describe 
survival data. Instead of the instantaneous hazard, it models the IR of an event of interest in a 
fixed time interval: if 𝑑 is the number events of interest in the interval, and 𝑦 is the length of 
the interval, this is simply 
𝐼𝑅 =
𝑑
𝑦
 
The Poisson model for survival data assumes that the log incidence rate is a linear function of 
the predictor variables: 
log(𝐼𝑅) = log(𝑑) − log(𝑦) = 𝛽଴ + 𝛽ଵ𝑥ଵ + 𝛽ଶ𝑥ଶ 
By bringing the log-time at risk to the right hand side, we get the equation 
log(𝑑) = log(𝑦) +  𝛽଴ + 𝛽ଵ𝑥ଵ + 𝛽ଶ𝑥ଶ 
Here, log (𝑦) is a constant offset term with fixed weight one that calibrates the observed event 
count for the time at risk, 𝛽଴ is the offset for the log-counts when both predictor variables are 
zero, and 𝛽ଵ and 𝛽ଶ are log IRR corresponding to a +1 change in the corresponding predictor 
variables. 
For a simple survival model with constant hazard rate ℎ(𝑡) = ℎ, the estimated hazard rate is 
just the IR, and the hazard ratio is estimated by the IRR above. By splitting follow-up time into 
suitably small intervals where hazard is approximately constant, Poisson regression can 
approximate any kind of hazard function with a piecewise constant step function. In practice, 
this often leads to very similar results as for classic survival models like Cox regression. 
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In Study IV, we used Poisson regression to estimate IRs of MI/IS and CVD preventive drug 
prescriptions (statins, ACE-inhibitors, ARBs), and estimate corresponding IRRs between SEP 
levels. 
4.3.6 Bootstrapping 
To deal with the uncertainty in the error distribution in the log-linear model for Poisson model 
used in Study IV,182,183 bootstrap resampling was used.184,185 Bootstrapping generated and 
analyzed a pre-defined sets of data from the original data in order to determine standard errors 
and confidence interval. 
4.3.7 Causal mediation analysis 
Causal mediation analysis186 identify and process the underling relationship between the 
exposure of interest and the outcome, through a covariate, known as mediator variable (Figure 
9). In study III causal mediation analysis was performed to evaluate and estimate possible 
mediation path in the association between educational level and atherosclerosis biomarkers. 
Causal mediation require some assumptions,187 which we have tried to deal with in Study III. 
  
 
Figure 9. DAG of causal relationship of the association between educational level and atherosclerosis biomarkers 
mediated throw lifestyle factors. 
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5 STUDY SUMMARY  
5.1 STUDY I 
5.1.1 Objective  
We analyzed absolute and relative temporal trends in incidence of MI and IS across different 
SEP strata from 1987 to 2010 for the entire Swedish population stratified by sex and age. 
5.1.2 Method 
Age is the main risk factor for MI and IS, therefore a natural timescale for a time-to-event 
analysis should be attained age. However we aimed to investigate the trends in IRs over time 
by SEP, therefore a more interesting timescale was the calendar year. Age was instead treated 
as second timescale grouped in 5-year intervals. 
A population-based cohort study was establish using Swedish national registers (see section 
4.1). All individuals resident in Sweden and born between 1932 and 1960, free from MI or IS 
in 1987 and who had information on SEP in the 1990 or 1980 Censuses were followed from 
1987 to 2010. The first primary incident cases upon discharge of MI and IS were retrieved from 
NPR (non-fatal) or primary cause of death from CDR (fatal). The exposure was derived from 
SEI and categorized in five SEP groups (Table 1, section 4.1). The most advantaged SEP group 
was HN-M and intermediate SEP groups included LN-M, SE, HM, and the most disadvantaged 
SEP group was LM. The TPR was used to link information on sex, birthdate and country of 
birth, see Figure 10 for cohort selection. Almost 3 million individuals were included in time-
to-event analysis (see section4.3.3) and followed from 1987 to occurrence of an event of MI/IS 
or censoring (migration, death) whichever came first. FPM (see section 4.3.4) was used with 
calendar year as primary timescale, and attained age as a secondary timescale (via stratification 
in four different age groups). Regression models were stratified by sex and attained age, and 
adjusted for birth country. IR per 100,000 person-years and IRR across SEP was estimated and 
presented in tables and graphically. 
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Figure 10. Cohort selection for Study I from Swedish national registers. 
5.1.3 Results 
Over the follow-up period, 121,496 MI cases (83% non-fatal, 17% fatal) and 61,421 IS cases 
(96% non-fatal, 4% fatal) were registered. There were large SEP inequalities in the incidence 
of MI/IS for both men and women, across all age groups (Figure 11, Figure 12). In men, the 
incidence in MI decreased over time for all SEP groups. While in women, the  IRs in MI were 
stable over time (Figure 11). 
Table 4 presents result summary of IRR comparing (LM, HM, SE, LN-M) with HN-M over 
time. Regarding MI, the IRRs comparing LM to HN-M were stable among men and women 
(Table 4). 
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Figure 11. IR of MI by SEP among Swedish men and women in three age groups. 
Table 4. Result summary, changes in IRR of MI and IS by SEP compared to HN-M from 1987 to 2010. 
Note:    Decreasing SEP differences; — stable SEP differences;    increasing SEP differences 
  Myocardial infarction Ischemic stroke 
SEP Age Men Women Men Women 
LM/HN-M 55-59 — —   
 60-64 — — —  
 65-69 — —   
HM/HN-M 55-59 — —   
 60-64   — — 
 65-69 —  —  
SE/HN-M 55-59 — —   
 60-64 — — — — 
 65-69 — — — — 
LN-M/HN-M 55-59  —   
 60-64 — — — — 
 65-69 — — — — 
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For IS, the IRs decreased over time among men, whereas IRs were more stable over time for 
women. There were large SEP inequalities in IS incidence among both men and women (Figure 
12). The IRR comparing LM to HN-M increased over time, particularly in women (Table 4). 
For the intermediate SEP groups the IRRs increased in the youngest age group (55-59), while 
in older age groups (60-65 and 65-69), the IRRs were stable over time (Table 4). 
 
Figure 12. IR of IS by SEP among Swedish men and women in three age groups. 
5.2 STUDY II 
5.2.1 Objectives 
We analyzed changes in short-term and long-term CFRs in MI and IS across SEP between the 
periods 1990-1994 and 2005-2009 by age and sex for the entire Swedish population. 
5.2.2 Method 
We aimed to study case-fatality over time from 1987 to 2010. Initially we aimed for a model 
with a four-way interaction with SEP, time-period (continuous 1987-2010), age and sex. 
Because this model would not converge, we had to simplify it. We analyzed changes over time, 
by selecting two time-periods, one at the beginning of the study period 1990-1994 and the 
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second at the end 2005-2009. We stratified our model between the two study periods and 
analyzed the case-fatality in each study period.  
Since the mortality rate from IS and in particularly from MI is very high within the first day 
after an event, it was not meaningful to analyze the whole follow-up period. In order to deal 
with the fact that almost one third of all MI events deceased within one day, we divided the 
follow-up period in short-term case-fatality (death within one day) and long-term case-fatality 
(survived first day). 
To identify the study population we used Swedish national registers (see section 4.1). NPR and 
CDR were used to identify all cases of first primary MI and IS in the two study periods, 1990-
1994 and 2005-2009. The main exposure of interest, SEP, was identified from Censuses 1990 
or 1980 and was categorized in five SEP groups as explained above in (Table 1, section 4.1). 
All Swedish born individuals were then followed from date of MI/IS diagnosis until death, 
emigration, end of follow-up (that is, 1 year after the diseases event) whichever came first (see 
Figure 13 for study flowchart). Short-term CFR, defined as death within one day after event, 
was estimated using logistic regression (see section 4.3.2). Subjects who survived the first day 
were included in time-to-event analysis (see section 4.3.3) using FPM (see section 4.3.4) and 
followed for one year, with time since disease event as underlying timescale. Age was included 
as a spline term for modelling the association between continuous age and mortality. Short-
term and long-term CFRs and CFRD per 1000 subjects were estimated in both study periods 
and presented at three pre-specified ages (55, 65 and 75 years) in tables and graphically. 
 
Figure 13. Flow chart for Study II. 
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5.2.3 Results 
In 1990-1994 almost 28% of all MI events were fatal, while in 2005-2009 21% of all MI events 
were fatal. See Table 5 for crude numbers. 
Table 5. Number of fatal and non-fatal events of MI and IS in two periods 1990-1994 and 2005-2009. 
 Myocardial infarction Ischemic stroke 
 1990-1994 2005-2009 1990-1994 2005-2009 
Total events 55,456 72,883 24,046 53,213 
Short-term events 15,726 (28%) 15,425 (21%) 2,152 (9%) 3,562 (7%) 
Long-term events 2,834 (7%) 4,847 (8%) 1,822 (8%) 4,844 (10%) 
For all SEP groups short-term CFR for MI and IS deceased over time from 1990-1994 to 2005-
2009 among both men and women (Figure 14 for MI, Figure 15 for IS). In the latest study 
period the most disadvantaged LM group had lower short-term CFR both in MI and IS than the 
most advantaged (HN-M) group had at the beginning of the follow-up period. 
 
Figure 14. Short-term CFR in MI by SEP among men and women at ages 55, 65 and 75 years in 1990-1994 and 
2005-2009. 
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Result summary of CFRDs between study periods from 1990-1994 to 2005-2009 for short- and 
long-term in MI and IS among men and women is presented in Table 6. 
CFRD for both short-term and long-term MI between the lowest and the highest SEP group 
remained stable over the study period among both men and women. While the intermediate 
SEP groups (HM, SE, LN-M) manage to catch-up with similar CFRs as HN-M (Table 6). For 
IS the short-term CFRD decreased for all SEP groups compared to HN-M in all ages among 
both men and women, except for women 55 years. While long-term CFRD in IS remained 
fairly stable over time (Table 6). 
Table 6. Result summary, changes in short-term and long-term CFRD of MI and IS by SEP compared to HN-M 
from 1990-1994 to 2005-2009.  
Note:    Decreasing SEP differences; — stable SEP differences;    increasing SEP differences 
  Myocardial infarction Ischemic stroke 
  Short-term Long-term Short-term Long-term 
SEP Age Men Women Men Women Men Women Men Women 
LM/HN-M 
55 — — —   —   
65 — — —   —   
75 — — —   —   
HM/HN-M 
55       — — 
65 —      —  
75 — —       
SE/HN-M 
55       — — 
65 —      — — 
75 — — — —     
LN-M/HN-M 
55   —    — — 
65   —    — — 
75  — —      
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Figure 15. Short-term CFR in IS by SEP among men and women at ages 55, 65 and 75 years in 1990-1994 and 
2005-2009. 
5.3 STUDY III 
5.3.1 Objectives 
We assessed the association between educational level and vascular- as well as cardiac 
biomarkers. Potential impact of body mass index (BMI), smoking and alcohol intake as 
mediators were investigated. 
5.3.2 Method 
Data from the PIVUS (see section 4.2), with atherosclerosis biomarkers, collected at age 70 
was used. The outcomes were defined as atherosclerosis biomarkers and were divided into 
eight vascular biomarkers including EDV and EIDV measured via the invasive forearm test as 
forearm blood flow to define the endothelial dysfunction. FMD was recorded by ultrasound of 
the brachial artery. IMT and number of plaques in CCA (carotid plaques) were detected by 
ultrasound of the CCA, CCA distensibility and (IM-GSM) were measured and SV/PP ratio was 
calculated. To assess the cardiac biomarkers (seven biomarkers), a Doppler echocardiography 
was performed to measure LA, LVEDD, RWT and calculate LVMI, E/A ratio, IVRT and EF; 
for further explanation of the outcomes see section 4.2. Main exposure of interest was measured 
as educational level, which was used as a proxy for SEP. The association between educational 
level (treated as a continuous variable) and the continuous outcomes where performed using 
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linear regression adjusted for sex (see section 4.3.1). For the association between educational 
level and the carotid plaques (treated as ordinal categorical variable with three category) ordinal 
logistic regression was used (see section 4.3.2). Possible role of modifiable lifestyle factors, 
including BMI, smoking and alcohol intake as potential mediators were evaluated via 
mediation analysis (see section 4.3.7). 
5.3.3 Results 
In total, 1,005 individuals were included in the analysis. We found an association between 
educational level and two of the vascular biomarkers, EIDV and carotid plaques (Figure 16 
upper panel A). Regarding the cardiac biomarkers, we found an association between 
educational level and LVMI, IVRT, LVEDD, LA and EF (Figure 16 lower panel B) 
 
Figure 16. Forest plot for the association between educational level and vascular-, cardiac biomarkers in PIVUS 
study adjusted for sex (mean and 95% CI) 
We further found that BMI mediated the pathways between educational level and EIDV by 
33% and most of the cardiac biomarkers by 15%-66% (see Table 7), while smoking or alcohol 
intake did not mediate the association. 
Carotid plaques
IMT
IM-GSM
FMD
EDV
SV/PP
CCA
EIDV
Coefficient
-0.22 (-0.36, -0.08)
-0.05 (-0.13,  0.02)
-0.03 (-0.11,  0.04)
 0.02 (-0.06,  0.10)
 0.03 (-0.05,  0.11)
 0.05 (-0.03,  0.12)
 0.07 (-0.01,  0.14)
 0.10 ( 0.02,  0.18)
-0.4 -0.3 -0.2 -0.1 0 0.1 0.2
(A) Vascular biomarkers
 
LVMI
IVRT
LVEDD
LA
RWT
EA Ratio
EF
Coefficient
-0.18 (-0.25, -0.10)
-0.14 (-0.21, -0.06)
-0.09 (-0.16, -0.02)
-0.09 (-0.17, -0.02)
-0.02 (-0.10,  0.05)
 0.01 (-0.07,  0.08)
 0.09 ( 0.01,  0.17)
-0.3 -0.2 -0.1 0 0.1 0.2
(B) Cardiac biomarkers
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Table 7. Mediation analysis of BMI, smoking and alcohol intake in the association between educational level 
and vascular-, cardiac biomarkers. 
  Body Mass Index a. Smoking b. Alcohol intake c. 
Carotid plaques NID 0.01 (-0.003; 0.03) -0.02 (-0.04; 0.004) -0.0001 (-0.001; 0.001) 
 NDE -0.2 (-0.3; -0.1) -0.2 (-0.3; -0.1) -0.2 (-0.3; -0.1) 
 ME(%) -7 10 0 
EIDV NID 12.1 (4.4; 19.8) 2.3 (-1.3; 5.9) -0.03 (-0.7; 0.6) 
 NDE 24.2 (-8.7; 57.2) 35.0 (1.6; 68.5) 36.6 (3.2; 70.0) 
 ME(%) 33* 6 0 
LVMI NID -1.7 (-2.7; -0.8) 0.2 (-0.1; 0.5) -0.0004 (-0.01; 0.01) 
 NDE -3.1 (-4.8; -1.3) -4.9 (-6.9; -3.0) -4.7 (-6.7; -2.7) 
 ME(%) 36* -5 0 
IVRT NID -1.1 (-1.8; -0.4) 0.1 (-0.2; 0.3) 0.01 (-0.2; 0.2) 
 NDE -4.8 (-8.0; -1.6) -6.0 (-9.2; -2.7) -5.8 (-9.1; -2.6) 
 ME(%) 19* -1 0 
LA NID -0.8 (-1.3; -0.4) 0.1 (-0.03; 0.3) -0.001 (-0.01; 0.01) 
 NDE -0.4 (-1.2; 0.4) -1.4 (-2.3; -0.5) -1.3 (-2.2; -0.3) 
 ME(%) 66* -11 0 
LVEDD NID -0.4 (-0.7; -0.2) 0.1 (-0.03; 0.2) -0.001 (-0.02; 0.02) 
 NDE -0.7 (-1.4; 0.1) -1.1 (-1.9; -0.3) -1.0 (-1.8; -0.3) 
 ME(%) 39* -7 0 
EF NID 0.002 (0.0003; 0.004) 0.0004 (-0.001; 0.001) 0.00004 (-0.001; 0.001) 
 NDE 0.01 (-0.00001; 0.03) 0.01 (0,002; 0.03) 0.01 (0.002; 0.03) 
 ME(%) 15* 2 0 
Note: Abbreviations: NID: Natural indirect effect; NDE: Natural direct effect; ME: Mediated effect in percent 
Carotid plaques, number of arteries with plaques; EIDV, endothelium-independent vasodilation; LVMI, left ventricular mass 
index; IVRT, left ventricular isovolumic relaxation time; LA, left atrial dimension; LVEDD, left ventricular diameter in end 
diastole; EF, ejection fraction. 
a. Body mass index was used as continues mediator. 
b. Smoking was grouped in (0 = “never smoker” or “former smoker”; 1 = “current smoker”) 
c. Alcohol intake was grouped in (0 = “Less than 24 grams per week for female” or “Less than 36 grams per week for male”; 
1 = At least 24 grams per week for female” or “At least 36 grams per week for male”) 
5.4 STUDY IV 
5.4.1 Objectives 
We studied the association between SEP and CVD preventive drugs according to needs. 
Further we investigate the differences in prescription of lipid lowering drugs statins and two 
antihypertensive drugs, first line treatment ACE-inhibitors and second line treatment ARBs. 
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5.4.2 Method 
Because disadvantaged SEP groups are more likely to suffer from CVD, they are in more need 
of CVD preventive drugs. In order to measure the need for medication in each SEP group, we 
selected two proxies for need: the ratio in MI/IS incidence in a “healthy” population (that is, 
free from CVD), and its comorbidities (diabetes, high blood pressure and high lipids level). 
This approach has been used previously in a Danish study.188 
Based on Swedish national registers (see section 4.1), a population-based cohort study was 
established. We included all Swedish individuals born before 1960, with information on SEP, 
free from ischemic heart disease (IHD) including MI, stroke (including IS), diabetes, and not 
having received a prescription of statins, ACE-inhibitors or ARBs before start of follow-up. 
Information on CVD diagnosis was included from NPR and CDR both as primary and 
secondary diagnosis (for ICD-codes see Table 2, section 4.1). Prescription information was 
retrieved from SPDR (for ATC- codes see Table 3, section 4.1). Individuals were followed 
from July 1, 2006 until registration of first occurrence of IHD, stroke, diabetes, a CVD 
preventive treatment (statins, ACE-inhibitors, ARBs), diabetes treatment, death, migration, or 
end of study (December 31, 2013), whichever came first. 
Time-to-event analysis was performed (see section 4.3.3), following each individual from July 
1, 2006 until outcome (first prescription of statins, ACE-inhibitors or ARBS) or censoring. 
Need-standardized IRs of combined CVD drug treatment (statins, ACE-inhibitors, ARBs) were 
calculated, IRRs in MI/IS were used as need proxies to adjust for unequal needs across SEP 
groups (five groups see Table 1, section 4.1). Moreover, need-standardized IRs of each of the 
drugs statins, ACE-inhibitors and ARBs were also calculated applying MI and IS IRR as two 
need proxies.  
To quantify the inequity in CVD preventive treatment, Poisson regression (see section 4.3.5) 
was used to calculate IRRs of need-standardized treatment across SEP with lowest SEP (LM) 
as reference group. To account for the additional uncertainty introduced in the Poisson 
regression bootstrapping was used to calculate the 95% CI for the IRRs (see section 4.3.5). 
Horizontal inequity (see section 2.4) for a SEP group relative to lowest SEP was noticed in 
case of a IRR>1. 
5.4.3 Results 
In total 2,357,351 individuals were included in the follow-up. The main results on need-
standardized incidence of the combined CVD treatment applying MI/IS IRR as need proxies 
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are presented in Table 8. We found that statins, ACE-inhibitors and ARBs to a larger extent 
were prescribed to individuals in disadvantaged SEP groups, but this did not always meet the 
needs. We found that the typically first-line recommended antihypertensive treatment (ACE-
inhibitors) almost reached horizontal equity across SEP groups, particularly when using IS 
incidence as need proxy (Figure 17). However, for lipid lowering statin drugs and for second-
line antihypertensive treatment ARBs, which have less side effects, larger SEP inequalities 
were found (Figure 16 & Figure 17). 
Figure 16. Horizontal inequity in need-standardized incidence treatment in statins, ACE-inhibitors and ARBs, 
by age, sex and SEP: applying MI IRR as need proxy. 
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Figure 17. Horizontal inequity in need-standardized incidence treatment in statins, ACE-inhibitors and ARBs, 
by age, sex and SEP: applying IS IRR as need proxy. 
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6 METHOD CONSIDERATION 
6.1 STUDY DESIGN 
The epidemiological study design in Study I, II and IV in this thesis was population-based 
cohort studies. In this type of studies, a defined population is followed longitudinally to assess 
the association between the exposure and outcome.92,189 The advantage of population-based 
cohort studies in Sweden is the ability to link information from several population-based 
registries, enabling longitudinal follow-up of a study cohort over time and also that the results 
can be applied to a wide range of the population gives the opportunity to study unselected 
population with high precisions. On the other hand, one has to rely on existing information 
because register data is restricted to few variables. Unfortunately, we did not have information, 
on for example, personal characteristics or on modifiable lifestyles factors (e.g. smoking, 
physical activity, BMI). However, these factors have been considered as mediating factors and 
not as confounders. In this thesis, SEP is considered to involve all modifiable lifestyle factors. 
6.2 VALIDITY IN EPIDEMIOLOGICAL STUDIES 
In epidemiological studies, errors in estimations can be either random or systematic. Systematic 
errors may bias the results and interpretations of studies. The validity of a study reflects whether 
the results are trustworthy and meaningful, and can be divided into internal and external 
validity. While internal validity relates to how reliable the estimates are in supporting the 
findings of the study, external validity relates to how generalizable these findings are. The 
largest threat to internal validity is bias due to selection, information and confounding.92  
Selection bias: Selection bias in Study I, II and IV was minimized, given that we used the total 
population register that includes all individuals and has no loss to follow-up. In the third study, 
50% of those invited to join the study had participated. To try to evaluate this bias, we examined 
the characteristics of CVD and medication use in a sample of 100 non-participants. On average, 
non-participants had a similar prevalence of MI, revascularization, as well as antihypertensive, 
statins and insulin treatment, but had a higher prevalence of diabetes, heart failure and stroke. 
While poorer participation rates are often seen among individuals with a low education, as well 
as those with higher smoking and alcohol intake,190-192 unfortunately this data was unavailable 
for this sample. It is possible that our limited findings of a mediating effect of smoking and 
alcohol intake on the association between SEP and CVD is due to underestimation caused by 
selection bias. Additionally, for the association between vascular and cardiac biomarkers, the 
association may be attenuated due to selection bias. 
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Information bias: In Study I, II and IV, information bias of exposure could be due to missing 
information on SEP from the Censuses. Individuals with an unclassifiable occupation are 
usually those outside the labor market, who also tend to have the highest CVD mortality.193 
This group is heterogeneous and can include individuals who are on long-term sick leave, 
retired, maternity leave, or students, therefore determining their SEP is difficult. For other SEP 
groups, the SEI occupation was based on self-reported occupation, and was additionally 
confirmed through information from the employer in the Labor market register (see section 
4.1). A proportion of the unclassified group had occupational information (as confirmed from 
employer), but because this information was missing in the self-reported questionnaire or was 
illegible, SEI could not be assigned. Another challenge is related to the multiple birth cohorts 
in Study I, II and IV; we selected all individuals born before 1960 and measure their SEP in 
1990. At this point, some individuals may have been too young to achieved their highest SEP, 
while others may have been too old on the labor market. To minimize this bias (for the elderly), 
we retrieved SEP from 1980 (if available) for those individuals with missing SEP information. 
However, for the youngest individuals, we did not have any information on SEP after 1990. 
In the third study, only 11 individuals were excluded from the analysis due to missing 
information on education. We cannot rule out possible exposure information bias due to the 
misclassification of self-reported education due to recall bias. Unfortunately it were not 
possible to validate these self-reports with other data.  
Regarding, possible information bias of the outcomes, MI and IS, were retrieved from NPR 
and CDR (Study I), fatal MI or IS from CDR (Study II short-term mortality), all-cause mortality 
from CDR (Study II long-term mortality) and first prescription of CVD preventive drugs 
(statins, ACE-inhibitors and ARBs) from SPDR (Study IV). The largest source of error would 
be the misclassification of MI and IS as causes of death from CDR (Study I and II short-term 
mortality), due to uncertainty of doctor's determination and reporting of the cause of death. 
Autopsies are one way to minimize such bias, however the rate of autopsy in Sweden has 
decreased substantially over time, especially for the elderly.194 Additionally, older individuals 
often suffer from multi-morbidities, which may make it difficult for the physician to determine 
which conditions were crucial for the death. Given this, cause of death is usually more valid 
for younger than for older individuals. However, the overall validity in CDR is high146 and the 
agreement for IHD between the underlying cause of death in the death certificate (on which the 
CDR is based) and the assessment of case summaries is as high as 87%.195 Despite this, it is 
difficult to know to which degree this misclassification is differential based on SEP groups. 
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Information bias for outcomes based on the NPR are probably minor, with the positive 
predictive values of MI and IS diagnoses being 85-100% (see section 4.1).145  
The SPDR includes prescribed and dispensed drugs, therefore information bias for outcomes 
in this register may be due to non-dispensed drugs. Additionally, drugs given in hospitals and 
nursing homes are not included in the SPDR. To limit this misclassification, we delayed study 
entry by one year to allow for issuing a prescription. Despite this, we cannot rule out the 
possibility of having misclassified some treated individuals as untreated in our analysis. While 
these patients would only contribute to an untreated risk-time until a prescription was issued. 
Still this bias can be differential between SEP groups, although it is not clear to what extent. 
Information from The National Board of Health and Welfare and Swedish eHealth Agency 
show that >99% of all the prescribed drugs statins, ACE-inhibitors and ARBs are included in 
the SPRD (personal communication).  
Confounding: If a factor is associated with both the exposure and outcome, and is not in the 
causal pathway between the exposure and the outcome, it may act as a confounder if not taken 
into account. The association between an exposure and outcome can be underestimated, 
overestimated or reversed due to confounding, and this may lead to misleading findings.92 
There are several strategies to deal with confounding in cohort studies, including restrictions 
during the study design stage, stratification, and adjustment (through data modelling).196 
In Study II and IV, we restricted to include only those born in Sweden, to remove confounding 
by indication through country of birth; while in the first study we adjusted for country of birth. 
To deal with the confounding effects of age and sex, we stratified for both these variables in 
Study I; while in Study II and IV we adjusted for age and sex. 
Birth county from the TPR and civil status from the Censuses where tested as other unmeasured 
confounders, however information was missing on current county of residence and current civil 
status. 
Confounding by indication is most notable in pharmacoepidemiology. In Study IV, the greatest 
challenge in considering the association between SEP and CVD drug use is that the prevalence 
of CVD varies by SEP. This means that prescription of CVD preventive drugs could also differ 
by SEP due to comorbidity. Stratification at the design stage was done to account for this sort 
of confounding, by excluding all individuals with prior CVD morbidity (including only those 
who were free from CVD, diabetes, and who had not received a prescription of statins, ACE-
inhibitors or ARBs). Additionally, our approach in calculating a need proxy as the IRR of MI/IS 
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was another step to account for the confounding effect of CVD preventive drugs across SEP 
groups. 
6.3 ETHICAL CONSIDERATIONS 
Study I, II and IV, included in this thesis is based on data from record linkage of Swedish 
registers. According to the Swedish Personal Data Act (PUL) and the European General Data 
Protection Regulation (GDPR), the data included in the national registers are considered as 
personal data. The data used in those three studies was unidentifiable and protected in database 
servers at the department. The national registers are governed by law and individuals included 
are not able to drop out from the registers. Study III is based on questionnaire and clinical test, 
which required that participants provided written informed consent. All studies based on 
personal data have to be approval by regional ethical review board. Which judge weather the 
potential benefits from the studies are greater than the potential harm. Ethical approval for 
Study I, II and IV were obtained from Regional ethical Review Board in Stockholm with diary 
numbers: 03-466, 2008/1482-32, 2009/1084-32 (Study I,II) and diary numbers: 2013/862-31/5, 
2016/1214-32, amendment 2018/2035-32 (Study IV). In addition, Regional Ethical Review 
Board in Uppsala obtained ethical approval for Study III, with diary number: 2015/252. 
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7 DISCUSSION 
7.1 MAIN FINDINGS 
7.1.1 Trends in SEP inequalities in CVD (Study I and II) 
In Study I and II we investigated absolute and relative SEP inequalities in incidence and case-
fatality in MI and IS over two decades. We aimed to explore how the decrease in CVD 
incidence and case-fatality have been distributed between SEP groups and if the gap in SEP 
inequalities for CVD is closing.  
We found there are large SEP inequalities in incidence and case-fatality in MI and IS. Overall 
incidence rates and case-fatality rates in MI have declined substantially over time in Sweden 
across all SEP groups. Particularly in short-term CFR in MI and IS where socioeconomic 
disadvantaged group had smaller short-term mortality in 2005-2009 than the most advantaged 
group had in 1990-1994. However among women, the incidence in MI and IS has not improved 
at similar extent. 
Regarding trends in SEP inequalities, we found that inequalities in incidence of MI and IS did 
not decrease over time, particularly between the most and least disadvantaged LM and HN-M 
groups. In addition, absolute differences in case-fatality for MI have mostly remained stable 
over time, but increased for long-term CFR among women. However, we found decreasing 
SEP inequalities in short-term CFR for IS. 
Previously, it has been found that SEP inequalities in MI incidence were stable over time,40,117 
or even increasing.128,197,198 A more updated study from northern Sweden, has shown a stable 
trend in educational inequalities of CVD morbidity and widening income inequalities.129 Also, 
data downloaded from The National Board of Health and Welfare show stable educational 
inequalities in MI incidence over time in Sweden (see Figure 8 in section 2.5).  
Comparatively few studies have investigated the trends in SEP inequalities in CVD case-
fatality, both in Sweden and Europe. Previous studies have found persistent SEP inequalities 
in short-term case-fatality in MI among men and women.119,199 However, previous studies have 
mostly excluded death outside the hospitals or have reported an average of short-term and long-
term case-fatality, which could be biased by improvements in short-term CFR. A strength in 
our case-fatality study, was that we reported trends in inequalities for both short-term case-
fatality (including death outside the hospital) and long-term case-fatality. 
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Several factors may influence the observed persistent SEP inequalities in incidence of MI and 
IS, such as remaining inequalities in CVD risk factors.128 Recent studies, have found that SEP 
inequalities in smoking and alcohol intake have been stable among men but increased over time 
among women.200,201 In addition, SEP inequalities in obesity and cholesterol levels have 
remained stable over time.202 However, high blood pressure have decreased across SEP over 
time.203-205 
Short-term case-fatality is a proxy for disease severity, awareness of early symptoms, the 
emergency transport system and emergency care. The large decrease in case-fatality in MI and 
IS across all SEP might largely be explained by improvements in modifiable lifestyle factors 
and in emergency care, irrespectively of SEP. As mention previously in section 2.1.4, 
hypertension is the main risk factor for IS. We therefore speculate that the decreasing SEP 
inequalities in short-term case-fatality in IS may be due to decreasing SEP inequalities in 
hypertension control.  
Long-term case-fatality, on other hand, is affected by both the severity of the disease and the 
clinical treatment following the event, such as revascularization. SEP inequalities have been 
found in treatment at coronary care units after first MI, as well as access to cardiac procedures 
and revascularization procedures 124,125,206 Contradictive results have been reported regarding, 
inequalities and medication after a CVD event.207-209 
Our studies contributes to the knowledge showing that SEP inequalities in incidence and case-
fatality of MI and IS have remained stable over time and even increased in some groups such 
as women and younger persons. Importantly, even if we can report that there have been major 
improvements in incidence and case-fatality of MI and IS, we are far from closing the gap in 
inequalities related to these disorders. 
7.1.2 SEP inequalities in atherosclerosis biomarkers. 
In Study III we found associations between educational level (as proxy for SEP) and vascular 
biomarkers (carotid plaques, EIDV) as well as most of the cardiac biomarkers (LVMI, IVRT, 
LA, LVEDD and EF), with higher SEP corresponding to more beneficial biomarker levels. In 
addition, BMI was found to mediate the associations between SEP and a majority of these 
biomarkers, explaining up to 66% of the association. However, we found no evidence for 
mediation effects of smoking or alcohol intake in the association of educational level and 
atherosclerosis biomarkers. 
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Regarding the vascular biomarkers, our results have been in line with previous studies that have 
found associations between SEP and carotid plaques.210,211 Contradictory results were reported 
previously in association between IMT and SEP,210,212 and we did not find an association 
between SEP and IMT.  
There has been less investigation of the association between SEP and cardiac biomarkers. Our 
findings confirm the previously reported results for the association between SEP and LVMI as 
well as for RWT, and E/A ratio.213,214 Inconsistent results were reported in the relationship 
between SEP and LA, EF,213,214 whereas an association was found in our study. 
From the mediation analysis we concluded that BMI was an important potential mediator of 
the association between SEP and vascular (EIDV) as well as cardiac (LVMI, EF, IVRT, 
LVEDD and LA) biomarkers. It has been reported that individuals with a higher BMI have 
increased cardiac preload and afterload, leading to high levels of peripheral resistance and high 
chronic volume overload.215,216 Another important role in the atherosclerotic process is that 
adipose tissue contributes to increased pro-inflammatory cytokine secretion.217 We did not find 
any evidence for mediation of smoking or alcohol intake in our data. This could be due to the 
small differences in smoking and alcohol intake prevalence across SEP, which does not allow 
the mediation effect to be captured. 
This study contributed to the evidence that SEP gradients are associated with subclinical 
biomarkers of atherosclerosis and that BMI is a mediator of the association between SEP and 
most of the those biomarkers. 
7.1.3 SEP inequalities in preventive treatment of CVD according to need 
In Study IV, we found that CVD preventive drugs such as statins, ACE-inhibitors and ARBs 
were prescribed to a larger extent to individuals in socioeconomically disadvantaged groups. 
However, due to an overall increasing need with decreasing SEP among men and women, the 
prescription pattern still did not meet the needs. Moreover, we demonstrated small SEP 
inequalities in first line recommended antihypertensive treatment (ACE-inhibitors) and large 
SEP inequalities in second line antihypertensive treatment ARBs and in lipid lowering statin 
drugs. 
Previous findings have demonstrated equity in prescription of CVD primary preventive 
treatment, or even that disadvantaged SEP groups were more often prescribed statins, ACE-
inhibitors, and ARBs compared to more advantaged SEP groups.135,136,138 This was confirmed 
in our study; however, it is not correct to conclude that there are no inequalities in CVD primary 
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preventive treatment. In fact, socioeconomically disadvantaged groups have higher risk of 
hypertension and high blood lipid levels due to poorer health and health-related behaviors (see 
section 2.1.4) and are probably in more need for medication. The horizontal equity, which the 
Swedish healthcare system is based on, requires access to healthcare based on need. Therefore, 
studies that do not consider the needs may result in biased and misleading findings. To deal 
with this, we used indirect standardization of MI/IS incidence as a proxy for need, in individuals 
free from CVD, diabetes and not receiving a prescription of CVD preventive treatments. This 
approach has been tested previously in a study that found education and income inequality in 
statins prescription in Denmark.188  
The horizontal inequity we found in prescription of CVD preventive treatments may suggest 
the impact of awareness, health literacy, health seeking behaviors and demands for treatment 
by socioeconomic advantaged group, but also by physicians’ decision to prescribe a treatment, 
that has previously been found to be associated with patients’ SEP.218 By analyzing the first 
prescription in two different antihypertensive drugs, we could observe differences in first and 
second line treatments. ACE-inhibitors should be prescribed as first line treatment and ARBs 
should be given as an alternative treatment in patients intolerant to ACE-inhibitors, according 
to guidelines. The larger SEP inequalities in second line treatment ARBs, which have less side 
effects, may illustrate the influence of demands, health literacy and health awareness among 
socioeconomic advantaged groups. 
The study has contributed to the knowledge that SEP inequalities in prevention treatment of 
CVD exist. In Sweden, treatment guidelines for hypertension are largely followed, but 
socioeconomically advantaged groups seem to benefit from larger use of second-line 
treatments for hypertension and statins. 
7.2 GENERAL DISCUSSION 
Regardless, of the large improvements in life expectancy and in modifiable risk factors over 
the last century, social gradient in CVD has persist over time.  
There is a vast literature on health inequalities. Different theories and explanations for why 
inequalities arise and how to solve it have been suggested. The Black Report in 1980,219 
suggested a process of social selection, which implies that inequalities in health are explained 
by a process of health related social mobility, where healthier individuals are more likely to 
move upwards in the social hierarchy and individuals with poor health are more likely to move 
downwards. Others have explained health inequalities in a life course perspective. Indicating 
that inequalities in adults is partly determinate by factors related to an individual’s childhood 
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situation,220 such as biological factor or social factors, such as access to material and immaterial 
resources.221,222 Also psychosocial stress, culture factors, or SEP differences in earlier adoption 
of new behaviors and new intervention, have been linked to persistent health inequalities.  
Neither the generous welfare states nor the technological developments in health care have 
been able to eliminate SEP inequalities in health. This is known in the literature as the Welfare 
States Paradox.223 Rather, it seems that the more developed welfare states and healthcare 
systems have enlarged the relative differences between SEP groups.132 However, at the same 
time, the quality of life and the decrease in incidence of CVD both in MI and IS have been 
substantial. We could show that disadvantaged SEP groups have lower case-fatality in the 2010 
than the highest SEP group had in the 1990. It has also been reported that Sweden has one of 
the lowest prevalence in Europe.7 
The debate is still ongoing and several reviews have measured different magnitudes of 
socioeconomic inequalities in health. Are the health inequalities increasing or decreasing? This 
important question remains, which has a high impact for public health policies: Is it more 
important to put the effort in healthcare and provide better health for all individuals or is it more 
important to decrease the inequalities in health. The Swedish national commission for equity 
in health has pointed out that inequalities in seven key resources have to be reduced to achieve 
the goal of decreasing health inequalities 6 Those key resources are “early life development; 
skills and education; working conditions and work environment; incomes and economic 
resources; housing and neighborhood conditions health behaviors; control, influences and 
participation”.6 
7.3 CONCLUSION 
Socioeconomically unprivileged groups have indeed benefited from recent changes in 
modifiable lifestyle factors and improved healthcare, which has resulted in decreasing 
incidence and case-fatality in CVD over time in Sweden. However, socioeconomic inequalities 
still exist both in absolute and relative terms. It is important to highlight that in women, the 
reduction in MI and IS incidence has been smaller than in men. 
Further, we can conclude that there are SEP inequalities in prevention of CVD by unequal 
prescription of preventive drugs according to need; in levels of atherosclerosis biomarkers; in 
incidence and survival in CVD. 
It is important to highlight that treatment for hypertension is almost equally distributed by SEP, 
which may indicate that implementation of clinical guidelines has been successful. This may 
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have been the reason of decreasing SEP differences in IS short-term case-fatality. This is an 
example of how the inequalities can be reduced by targeted prevention to equal health 
conditions for vulnerable groups. 
7.4 IMPLICATIONS AND FUTURE PERSPECTIVES 
Taken together, the amount of resources and prevention strategies are not the only factors 
driving health inequalities. Individual’s receptiveness for action, health literacy and social 
conditions might influence the outcome. From this thesis, we can show that in Sweden, a 
country based on equal access to healthcare according to need, it is not only a matter of 
unhealthy behaviors among lower SEP but also a matter of unequal healthcare use.  
Recent reports have emphasized that income inequality in Sweden is growing, with a widening 
gap between the rich and poor in Sweden. There are additional threats to the equal society in 
Sweden, which may increase the gap in equalities. For example, residential segregation is 
increasing,224 which plays an important role for early childhood conditions, education and later 
occupation and health conditions. In addition, several reports have stressed that obesity and 
illegal drugs are also an increasing issues in Sweden for future generations.225,226 
Some important questions are still unanswered. First, we have seen that women did not improve 
MI/IS incidence to similar extent as men. Previously, it has been reported that women may 
have different symptoms of MI and IS, and more research on sex and gender differences may 
shed light in this area. 
Furthermore, in this thesis we only investigated first prescription of either ACE-inhibitors or 
ARBs. More research should focus on the mechanism for prescription inequalities.  
Socioeconomically disadvantaged groups, may suffer from different comorbidities, it is also of 
interest to seek answer how those comorbidities affect the SEP inequalities in diagnosis of 
CVD and in drug use. 
Finally, based on our conclusions, as well as the evidence that MI/IS are affected by modifiable 
lifestyles factors, the society would benefit from more research with focus on targeted 
preventions strategies. 
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